The GIFT Nifty is a trading flat, indicating a muted start for the day.The S&P 500 and the Nasdaq ended higher while the Dow ...

BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had ...

Thursday’s weakness in Cytokinetics’ (CYTK) shares is likely due to commentary from Bristol Myers’ (BMY) earnings call, where the company ...

Quarterly Net Profit at Rs. 470.60 crore in December 2024 up 4.48% from Rs. 450.40 crore in December 2023. EBITDA stands at ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

From Toyota to the Tour de France, some companies have hidden surprising symbols, messages, or meanings in their world-famous ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Zydus Wellness Ltd has informed BSE regarding Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure<BR>Requirements) Regulations 2015 (the Listing Regulations) ...

She also writes biographies for Story Terrace. A share repurchase is a public company's reduction in its number of shares outstanding, accomplished by buying a portion of its shares on the open ...

Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...